Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
1. A method of treating a female subject undergoing embryo transfer, comprising
administering to the female subject an OBE001 oxytocin receptor antagonist:
(1) only during a time
a) between day 6 following luteinizing hormone (LH) surge (LH+6) and day 9 following LH surge (LH+9) of a natural ovulation cycle;
b) between day 6 following human chorionic gonadotropin (hCG) administration (hCG+6) and day 9 following hCG administration (hCG+9) of an induced ovulation cycle;
c) between day 6 and day 7 of a luteal phase support following oocyte retrieval; or
d) between day 6 and day 9 of a luteal phase support; or
(2) only on the day of transfer of an embryo, wherein the transferred embryo is a blastocyst-stage embryo.
2. The method of claim 1 , wherein the transferred embryo is a blastocyst-stage embryo.
3. The method of claim 2 , wherein the blastocyst-stage embryo has an expansion and hatching status of 3, 4, 5, or 6.
4. The method of claim 1 , wherein the antagonist is administered to the female subject on the same day as embryo transfer.
5. The method of claim 1 , wherein the antagonist is administered orally.
6. The method of claim 1 , further comprising transferring an embryo into the uterus, the uterine cavity, or the fallopian tubes of the female subject.
7. The method of claim 1 , wherein the antagonist is administered to the female subject between 2 hours prior to and 2 hours after embryo transfer.
8. The method of claim 1 , wherein the antagonist is administered to the female subject at day 5 post oocyte retrieval.
9. The method of claim 1 , further comprising administering luteal phase support to the female subject.
10. The method of claim 9 , wherein the luteal phase support comprises supplementation with progesterone, estradiol and progesterone, human chorionic gonadotropin, a progestin and/or a gonadatropin releasing hormone (GnRH) agonist.
11. The method of claim 1 , wherein the transferred embryo is a cleavage-stage embryo and the antagonist is administered to the female subject only during a time a) between day 6 following luteinizing hormone (LH) surge (LH+6) and day 9 following LH surge (LH+9) of a natural ovulation cycle; b) between day 6 following human chorionic gonadotropin (hCG) administration (hCG+6) and day 9 following hCG administration (hCG+9) of an induced ovulation cycle; c) between day 6 and day 7 of a luteal phase support following oocyte retrieval; or d) between day 6 and day 9 of a luteal phase support.
12. The method of claim 11 , wherein the cleavage-stage embryo is a day 2 or day 3 post-fertilization embryo.
13. A method of implanting an embryo in a female subject, said method comprising transferring an embryo into the uterus, the uterine cavity or the fallopian tubes of a female subject and administering to the female subject an OBE001 oxytocin receptor antagonist:
(1) only during a time
a) between day 6 following luteinizing hormone (LH) surge (LH+6) and day 9 following LH surge (LH+9) of a natural ovulation cycle;
b) between day 6 following human chorionic gonadotropin (hCG) administration (hCG+6) and day 9 following hCG administration (hCG+9) of an induced ovulation cycle;
c) between day 6 and day 7 of a luteal phase support following oocyte retrieval; or
d) between day 6 and day 9 of a luteal phase support; or
(2) only on the day of transfer of an embryo, wherein the transferred embryo is a blastocyst-stage embryo.
14. The method of claim 13 , wherein the antagonist is administered to the female subject at day 5 post oocyte retrieval.
15. The method of claim 13 , wherein the luteal phase support comprises supplementation with progesterone, estradiol and progesterone, human chorionic gonadotropin, a progestin and/or a gonadatropin releasing hormone (GnRH) agonist.
16. The method of claim 13 , wherein the transferred embryo is a cleavage-stage embryo and the antagonist is administered to the female subject only during a time a) between day 6 following luteinizing hormone (LH) surge (LH+6) and day 9 following LH surge (LH+9) of a natural ovulation cycle; b) between day 6 following human chorionic gonadotropin (hCG) administration (hCG+6) and day 9 following hCG administration (hCG+9) of an induced ovulation cycle; c) between day 6 and day 7 of a luteal phase support following oocyte retrieval; or d) between day 6 and day 9 of a luteal phase support.
17. The method of claim 13 , wherein the transferred embryo is a blastocyst-stage embryo, and wherein the antagonist is administered to the female subject on the same day as embryo transfer.
18. A method of treating a female subject undergoing embryo transfer, comprising: administering to the female subject (i) luteal phase support comprising progesterone, and (ii) an OBE001 oxytocin receptor antagonist on the same day a blastocyst-stage embryo is transferred to the female subject.